Abstract 609P
Background
Pembrolizumab, a checkpoint inhibitor, has revolutionized the treatment of advanced melanoma by harnessing the immune system to target cancer cells. However, its use is associated with immune-related adverse events, including vitiligo and thyroid function abnormalities. This study aims to investigate the association between thyroid function abnormalities and vitiligo induced by pembrolizumab, specifically focusing on the prognosis in patients with advanced melanoma.
Methods
A retrospective survey of medical records and treatment outcomes of patients with locally advanced/metastatic melanoma receiving pembrolizumab was conducted. The study reported data on the incidence of vitiligo, thyroid function abnormalities, and their impact on prognosis. Data was collected from multiple oncology centers across Iraq. Kaplan-Meier survival curves and Cox regression were used for statistical analysis.
Results
One hundred cases with advanced melanoma were included in this study. The mean age of the samples was 55.8 ± 15.5 years old. Male to female ratio was 0.79. The Incidence of vitiligo was reported to be 27%, mainly in the survived-group (35.2%, P-value = 0.046). It took an average of 12 weeks for the development of vitiligo. The incidence of thyroid dysfunction was found to be 22%. The development of vitiligo significantly improved survival in patients with advanced melanoma (log-rank test = 0.043). On the other hand, the occurrence of thyroid dysfunction as an immune-side effect to treatment did not have an effect on the overall survival of the cohort.
Conclusions
The findings of this study suggest that there is an association between the incidence of vitiligo induced by pembrolizumab and overall survival in patients with advanced melanoma. However, no such relationship was found in regard to the development of thyroid dysfunction.
Clinical trial identification
Editorial acknowledgement
Dr. Ahmed Z. Al-Samaraee, Medical oncologist, Oncology teaching hospital, Baghdad Dr Maha S. Sahib, Clinical Pharmacist, Baghdad Dr Ayad R Alasadi, Medical oncologist, Al-Amal Hospital, Baghdad.
Legal entity responsible for the study
Oncology Teaching Hospital, Medical City Complex, Baghdad.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract